Written By: IJCP Editorial Team

Published On: 27 Aug, 2022 12:40 PM | Updated On: 18 May, 2024 12:58 PM

Supplemental Oxygen in the Newborn: Historical Perspective and Current Trends

Oxygen is the final electron acceptor in aerobic respiration, whose scarcity may cause bioenergetic failure and cell death. Thus, administration of supplemental concentrations of oxygen to overcome barriers to tissue oxygen delivery (e.g., heart failure, lung disease, ischemia) saves dying cells in low cellular oxygen content conditions. 

Yet, oxygen delivery and consumption balance depend on tightly controlled oxygen gradients and compartmentalized redox potential. 

Although therapeutic oxygen delivery can be life-saving, it may disrupt growth and development, impair bioenergetic function, and induce inflammation. 

Preterm and term newborns are special populations having decreased antioxidant capacity and reliance on redox signaling for rapid growth and development. They are particularly vulnerable to hyperoxic injury due to oxidative stress.

Even after advances in neonatal care, supplemental oxygen remains the most commonly used drug in the NICU. 

The application of oxygen in neonatal medicine has seen a dramatic pendulum swing, from universal use both in the delivery room and beyond to intense restriction due to retinal disease concerns. 

The introduction of the pulse oximeter to initial newborn resuscitation and the NICU has permitted targeted oxygen therapy, while broad international collaboration has resulted in comprehensive data to support current guidelines. Still, pulse oximetry supplies little information for making therapeutic decisions, and supplemental oxygen remains a blunt and untargeted therapy. 

Future strategies must optimize oxygen delivery and minimize oxidative damage by utilizing NIRS monitoring or cellular, organ-and patient-specific antioxidant therapies.

Mathias M, Chang J, Perez M, Saugstad O. Supplemental Oxygen in the Newborn: Historical Perspective and Current Trends. Antioxidants (Basel). 2021 Nov 25;10(12):1879. DOI: 10.3390/antiox10121879. PMID: 34942982; PMCID: PMC8698336.